The antiproliferative activity of DMDC is modulated by inhibition of cytidine deaminase

Cancer Research

Volumn 58, Issue 6, 1998, Pages 1165-1169

  Eda, Hiroyuki ^a   Ura, Masako ^a   F Ouchi, Kaori ^a   Tanaka, Yutaka ^a   Miwa, Masanori ^a   Ishitsuka, Hideo ^a  

^a NIPPON ROCHE RESEARCH CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2' DEOXY 2' METHYLIDENECYTIDINE; CYTIDINE DEAMINASE; GEMCITABINE; TETRAHYDROURIDINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; COLON CARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME SUBSTRATE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CYTIDINE DEAMINASE; DEOXYCYTIDINE; ENZYME INHIBITORS; GROWTH INHIBITORS; HUMANS; MALE; MICE; MICE, NUDE; SUBSTRATE SPECIFICITY; TUMOR CELLS, CULTURED;

EID: 0032520918     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Baker, C. H., Banzon, J., Bollinger, J. M., Stubbe, J., Samano, V., Robins, M. J., Lippert, B., Jarvi, E., and Resvick, R. 2′-Deoxy-2′-methylenecytidine and 2'-deoxy-2′, 2′-difluorocytidine 5′-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase. J. Med. Chem., 34: 1879-1884, 1991.
2. Matsuda, A., Azuma, A., Nakajima, Y., Takenuki, K., Dan, A., Iino, T., Yoshimura, Y., Minakawa, N., Tanaka, M., and Sasaki, T. Design of new types of antitumor nucleosides: the synthesis and antitumor activity of 2′-deoxy-(2′-C-substituted) cytidines. In: C. K. Chu and D. C. Baker (eds.), Nucleosides and Nucleotides as Antitumor and Antiviral Agents, pp. 1-22. New York: Plenum Press, 1993.
3. Heinemann, V., Hertel, L. W., Grindey, G. B., and Plunkett, W. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res., 48: 4024-4031, 1988.
4. Huang, P., Chubb, S., Hertel, L. W., Grindey, G. B., and Plunkett, W. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res., 51: 6110-6117, 1991.
5. Heinemann, V., Xu, Y-Z., Chubb, S., Sen, A., Hertel, L. W., Grindey, G. B., and Plunkett, W. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′, 2′-difluorodeoxycytidine. Mol. Pharmacol., 38: 567-572, 1990.
6. Braakhuis, B. J. M., van Dongen, G. A. M. S., Vermorken, J. B., and Snow, G. B. Preclinical in vivo activity of 2′,2′-difluorodeoxycytidine (gemcitabine) against human head and neck cancer. Cancer Res., 51: 211-214, 1991.
7. Hertel, L. W., Boder, G. B., Stan Kroin, J., Rinzel, S. M., Poore, G. A., Todd, G. C., and Grindey, G. B. Evaluation of the antitumor activity of gemcitabine (2′, 2′-difluorodeoxycytidine). Cancer Res., 50: 4417-4422, 1990.
8. Yamagami, K., Fujii, A., Arita, M., Okumoto, T., Sakata, S., Matsuda, A., Ueda, T., and Sasaki, T. Antitumor activity of 2′-deoxy-2′-methylidenecytidine, a new 2′-deoxycytidine derivative. Cancer Res., 51: 2319-2323, 1991.
9. Ishitsuka, H., Miwa, M., Eda, H., Ura, M., Ouchi, K., Foley, L. H., and Keith, D. D. High susceptibility of human cancer xenografts with higher levels of cytidine deaminase to a new 2′-deoxycytidine antimetabolite DMDC. Proc. Am. Assoc. Cancer Res., 38: 315, 1997.
10. Bouffard, D. Y., Laliberte, J., and Momparler, R. L. Kinetic studies on 2′,2′-difluorodeoxycytidine (gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. Biochem. Pharmacol., 45: 1857-1861, 1993.
11. Takenuki, K. Matsuda, A., Ueda, T., Sasaki, T., Fujii, A., and Yamagami, K. Design, synthesis, and antineoplastic activity of 2′-deoxy-2′-methylidenecytidine. J. Med. Chem., 31: 1063-1064, 1988.
12. Tamura, S., Fujimoto-Ouchi, K., Mori, K., Endo, M., Matsumoto, T., Eda, H., Tanaka, Y., Ishitsuka, H., Tokita, H., and Yamaguchi, K. Involvement of human interleukin 6 in experimental cachexia induced by a human uterine cervical carcinoma xenograft. Clin. Cancer Res., 1: 1353-1358, 1995.
13. Lowry, O. H., Rosenbrough, N. J., Farr, A. L., and Randall, R. J. Protein measurement with the Folin phenol reagent. J. Biol. Chem., 193: 265-275, 1951.
14. 3. Biochim. Biophys. Acta, 1312: 99-104, 1996.
15. Chan, T., Lakhchaura, B. D., and Hsu, T-F. Differences in deoxycytidine metabolism in mouse and rat. Biochem J., 210: 367-371, 1983.
16. Pillwein, K., Jayaram, H. N., and Weber, G. Effect of ishema on nucleosides and bases in rat liver and hepatoma 3294A. Cancer Res., 47: 3092-3096, 1987.
17. Harkrader, R. J., Jackson, R. C., Ross, D. A., and Weber, G. Increase in liver and kidney deoxycytidine kinase activity linked to neoplastic transformation. Biochem. Biophys. Res. Commun., 96: 1633-1639, 1980.
18. Hanze, A. R. Nucleic Acids IV. The catalytic reduction of pyrimidine nucleosides (human liver deaminase inhibitors). J. Am. Chem. Soc., 89: 6720-6725, 1967.
19. Ruiz van Haperen, V. W. T., Veerman, G., Eriksson, S., Boven, E., Stegmann, A. P. A., Hermsen, M., Vermorken, J. B., Pinedo, H. M., and Peters, G. J. Development and molecular characterization of a 2′, 2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. Cancer Res., 54: 4138-4143, 1994.
20. Miura, S., Tanaka, M., Yoshimura, Y., Satoh, H., Sakata, S., Machida, H., Matsuda, A., and Sasaki, T. In vitro and in vivo antitumor activity of a novel nucleoside, 4′-thio-2′-deoxy-2′-methylidenecytidine. Biol. Pharm. Bull. (Tokyo), 19: 1311-1315, 1996.
21. Plunkett, W., Huang, P., Searcy, C. E., and Gandhi, V. Gemcitabine: preclinical pharmacology and mechanisms of action. Semin. Oncol., 23 (Suppl. 10): 3-15, 1996.
22. Neff, T., and Blau, C. A. Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine. Exp. Hematol., 24: 1340-1346, 1996.